

SOLTA MEDICAL INC  
Form 4  
January 27, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Ku Mingo**

(Last) (First) (Middle)

**C/O SOLTA MEDICAL, INC., 25881 INDUSTRIAL BLVD.**

(Street)

**HAYWARD, CA 94545**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**SOLTA MEDICAL INC [SLTM]**

3. Date of Earliest Transaction (Month/Day/Year)  
**01/23/2014**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**Vice President of Global Sales**

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D) Code V Amount (D) Price                                |   |  |                                   |
| Common Stock                    | 01/23/2014                           |  | D                              | 41,378 (1) D \$ 2.92  | 0   | D  |                                   |
| Common Stock                    | 01/23/2014                           |  | M                              | 5,963 (2) A (2) 5,963   |   | D  |                                   |
| Common Stock                    | 01/23/2014                           |  | D                              | 5,963 D \$ 2.92   | 0   | D  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control**

SEC 1474 (9-02)

number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Performance Restricted Stock Unit          | (2)  | 01/23/2014                           |  | M                              | 5,963   | (2) 02/04/2023   | Common Stock  | 5,963                      |
| Employee Stock Option (Right to Buy)       | \$ 1.37  | 01/23/2014                           |  | D                              | 20,000  | (3) 12/31/2018   | Common Stock  | 20,000                     |
| Employee Stock Option (Right to Buy)       | \$ 1.51  | 01/23/2014                           |  | D                              | 2,000   | (3) 07/31/2019   | Common Stock  | 2,000                      |
| Employee Stock Option (Right to Buy)       | \$ 2.75  | 01/23/2014                           |  | D                              | 3,000   | (3) 01/31/2021   | Common Stock  | 3,000                      |
| Employee Stock Option (Right to Buy)       | \$ 2.77  | 01/23/2014                           |  | D                              | 50,000  | (3) 12/11/2022   | Common Stock  | 50,000                     |
| Employee Stock Option (Right to Buy)       | \$ 2.56  | 01/23/2014                           |  | D                              | 2,500   | (3) 01/31/2023   | Common Stock  | 2,500                      |

## Reporting Owners

| Reporting Owner Name / Address                                | Relationships |           |                                |       |
|---|---------------|-----------|--------------------------------|-------|
|   | Director      | 10% Owner | Officer                        | Other |
| Ku Mingo<br>C/O SOLTA MEDICAL, INC.<br>25881 INDUSTRIAL BLVD. |               |           | Vice President of Global Sales |       |

HAYWARD, CA 94545

## Signatures

/s/ Mingo Ku

01/27/2014

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Disposed of pursuant to the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger"), at the merger consideration of \$2.92 per share (the "Merger Consideration"). Includes 28,166 shares deemed acquired pursuant to the grant of restricted stock units ("RSU s") on various dates. The vesting of the RSU's was accelerated in connection with the Merger.
- (1) Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.
  - (2) This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment equal to the product of (a) the number of shares underlying this option and (b) the difference between the Merger Consideration and the exercise price per share of this option.
  - (3)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.